Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade
I'm PortAI, I can summarize articles.
Invivyd Inc. (NASDAQ:IVVD) has selected VBY329 as a monoclonal antibody candidate for preventing Respiratory Syncytial Virus (RSV) in neonates, infants, and children. This decision was made on November 24, utilizing the company's proprietary antibody discovery technology. Despite an analyst downgrade, Invivyd is considered a promising multibagger penny stock.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments